含锂漱口水对头颈放疗口腔黏膜炎与味觉障碍的影响:1/2期临床试验
这项前瞻性单中心1/2期试验纳入175例接受根治性或术后辅助放疗的头颈癌患者,评估含锂漱口水对口腔黏膜炎(OM)和味觉障碍(TD)的效果与安全性。2期使用0.15 mol/L含锂漱口水,严重OM发生率显著低于安慰剂组(34.2% vs 52.1%;P = .0304),且含锂漱口水减少了放疗期间TD,安全性良好。
要点
- 含锂漱口水显著降低严重口腔黏膜炎发生率(34.2% vs 52.1%;P = .0304)。
- 含锂漱口水减少放疗期间味觉障碍,安全性良好。
- 2期剂量为0.15 mol/L,每日3次,放疗期间使用。
核心结论
- 含锂漱口水显著降低严重口腔黏膜炎的发生率和发生时间,安全性良好,并显示出改善放疗所致味觉障碍的潜力。
研究设计与样本
- 前瞻性单中心1/2期临床试验,纳入接受根治性或术后辅助放疗的头颈癌患者,1期15例、2期160例,共175例。
- 患者放疗期间每日3次接受含锂漱口水或安慰剂,1期评估剂量限制性毒性并确定2期剂量。
- 2期主要终点为严重口腔黏膜炎(SOM)发生率,次要终点包括SOM发生时间和持续时间、味觉改变、口干发生率、生活质量和安全性。
主要发现
- 2期含锂组SOM发生率显著低于安慰剂组(34.2% vs 52.1%;P = .0304)。
- 含锂组SOM发生时间较安慰剂组缩短(中位不可估计 vs 35.0天;P = .0262)。
- 含锂漱口水减少了放疗期间味觉障碍(TD)。
- 两组不良事件相似,未观察到严重锂相关不良事件。
关键数值与推荐
- 2期使用0.15 mol/L含锂漱口水,每日3次,放疗期间使用。
- 2期SOM发生率:含锂组34.2%,安慰剂组52.1%(P = .0304)。
- SOM发生时间:含锂组中位不可估计,安慰剂组35.0天(P = .0262)。
临床怎么用
- 头颈癌放疗期间可考虑每日3次使用0.15 mol/L含锂漱口水以降低严重口腔黏膜炎风险。
- 含锂漱口水安全性良好,未观察到严重锂相关不良事件,可探索用于改善放疗相关味觉障碍。
局限性
- 单中心研究,结果外推需谨慎。
- 1期样本量较小(15例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Oral mucositis (OM) and taste dysfunction (TD) are common oral complications of radiation therapy (RT) in patients with head and neck cancer, significantly impairing treatment outcomes and quality of life. The purpose of this study was to evaluate the effectiveness and safety of a lithium-containing mouthwash for managing OM and to explore its potential protective effect against TD. METHODS AND MATERIALS: This prospective single-institutional phase 1/2 trial enrolled patients with head and neck cancer undergoing definitive or postoperative adjuvant RT. Patients received a lithium-containing mouthwash or placebo 3 times daily during RT. The phase 1 study assessed its dose-limiting toxicity and determined the dose for phase 2. The primary endpoint in phase 2 was the incidence of severe OM (SOM). Secondary endpoints included time to onset and duration of SOM, taste alteration, incidence of dry mouth, quality of life, and safety. RESULTS: A total of 175 patients were enrolled: 15 in phase 1 and 160 in phase 2. Based on phase 1 results, phase 2 used a 0.15 mol/L lithium-containing mouthwash. In phase 2, the incidence of SOM was significantly lower in the lithium group than in the placebo group (34.2% vs 52.1%; P = .0304). The time to onset of SOM (median not estimable vs 35.0 days; P = .0262) was also shorter in the lithium group. Additionally, the lithium-containing mouthwash reduced TD during RT. Adverse events were similar between groups, and no severe lithium-related adverse events were observed. CONCLUSIONS: Lithium-containing mouthwash significantly reduced the incidence and time to onset of SOM, had a good safety profile, and showed potential to ameliorate irradiation-induced TD.
引用
- Li Z, Pei Y, Zhang Z, et al. Effect of Lithium Mouthwash on Oral Mucositis and Taste Dysfunction in Head and Neck Radiation Therapy: The Phase 1/2 Clinical Trial. Int J Radiat Oncol Biol Phys. 2026. PMID: 42628808. doi:10.1016/j.ijrobp.2026.08.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。